About MedGenome
MedGenome is a company based in Bengaluru (India) founded in 2013 by Mahesh Pratapneni. MedGenome has raised $264.5 million across 10 funding rounds from investors including HDFC, HDFC Mutual Fund and International Finance Corporation. The company has 883 employees as of April 05, 2024. MedGenome has completed 4 acquisitions, including Lifecode, Medcare Diagnostics and Prognosis. MedGenome offers products and services including Sequencing Services and Bioinformatics Services. MedGenome operates in a competitive market with competitors including Foundation Medicine, Personalis, Novogene Corporation, Lantern Pharma and Burning Rock, among others.
- Headquarter Bengaluru, India
- Employees 883 as on 05 Apr, 2024
- Founders Mahesh Pratapneni
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Medgenome Labs Limited
- Date of Incorporation 08 Apr, 2013
- Jurisdiction Bangalore South, Karnataka, India
-
Annual Revenue
$29.55 M (USD)9.65as on Mar 31, 2023
-
Net Profit
-$1.72 M (USD)-141.12as on Mar 31, 2023
-
EBITDA
-$1.58 M (USD)-128.46as on Mar 31, 2023
-
Total Equity Funding
$264.5 M (USD)
in 10 rounds
-
Latest Funding Round
$47.5 M (USD), Series E
Jul 21, 2025
-
Investors
HDFC
& 24 more
-
Employee Count
883
as on Apr 05, 2024
-
Investments & Acquisitions
Lifecode
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MedGenome
MedGenome offers a comprehensive portfolio of products and services, including Sequencing Services and Bioinformatics Services.
Offers DNA, RNA, and single-cell sequencing for research applications.
Provides analysis of genomic data for insights and publications.
People of MedGenome
Unlock access to complete
Unlock access to complete
Funding Insights of MedGenome
MedGenome has successfully raised a total of $264.5M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $47.5 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MedGenome
MedGenome has secured backing from 25 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include HDFC, HDFC Mutual Fund and International Finance Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Venture capital investments are provided by Sofina to emerging companies.
|
Locked | Locked | Locked | |
|
IFC is focused on private sector development in emerging markets.
|
Locked | Locked | Locked |
Investor details for MedGenome
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MedGenome
MedGenome has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Lifecode, Medcare Diagnostics and Prognosis.
Investment portfolio details for MedGenome
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of radiology, pathology, and other services
|
Locked | Locked | 2016 | Locked | |
|
Offers diagnostic imaging services like PET-CT and CT scans in Mumbai.
|
Locked | Locked | 2013 | Locked | |
|
Molecular tumor profiling panels for solid tumors are developed.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for MedGenome
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MedGenome
Detailed financials for MedGenome
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Medgenome Comparisons
Peer comparison for MedGenome
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MedGenome
MedGenome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Foundation Medicine, Personalis, Novogene Corporation, Lantern Pharma and Burning Rock, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
|
| Locked | Locked | Locked |
Personalized cancer diagnostics are developed using genomic big data analysis.
|
Detailed competitors of MedGenome
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Medgenome
Complete news archive for MedGenome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MedGenome
MedGenome was founded in 2013.
MedGenome is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Mahesh Pratapneni is the current CEO of MedGenome. They have also founded this company.
MedGenome is a funded company, having raised a total of $264.5M across 10 funding rounds to date.
As of Apr 05, 2024, the latest employee count at MedGenome is 883.
Annual revenue of MedGenome is $29.55M as on Mar 31, 2023.
MedGenome was founded in 2013 and is headquartered in Bengaluru, India, within the genomics and biotechnology sector. A range of services is offered, including whole genome and exome sequencing, single-cell sequencing, spatial transcriptomics, and immune profiling. Bioinformatics assistance, such as analysis pipelines and data visualization tools, is provided to support research efforts in rare diseases, cancer, and antibody discovery.
MedGenome's top competitors include Foundation Medicine, Personalis and Novogene Corporation.
MedGenome offers Sequencing Services and Bioinformatics Services.
MedGenome has made 4 acquisitions, including Lifecode, Medcare Diagnostics, and Prognosis.
MedGenome has 25 investors. Key investors include HDFC, HDFC Mutual Fund, International Finance Corporation, LeapFrog, and HDFC Life.